There is recent evidence that marijuana use has increased, and that a subset of marijuana smokers are seeking treatment for their marijuana abuse. These data, in combination with empirical evidence that marijuana dependence develops in humans, support the objective of this proposal to develop a model to assess the ability of pharmacological interventions to decrease marijuana use. Specifically, the acute and residual effects of smoked marijuana under both an active and placebo dose of study medication will be assessed. The underlying assumption of this proposal is that marijuana self-administration can be disrupted via several mechanisms. The following behaviors will be measured: marijuana self- administration, psychomotor task performance, social behavior, food intake, and subjective reports of drug effects.
Aim #1. Evaluate the ability of the anticonvulsant, divalproex, and the antidepressant, bupropion to decrease marijuana use indirectly by attenuating symptoms of smoked marijuana withdrawal. Hypotheses: these medications will I) attenuate symptoms of irritability, anxiety, and depression during marijuana abstinence, and 2) correspondingly, reduce marijuana self-administration after a period of monitored marijuana abstinence.
Aim #2. Evaluate the ability of the mu-opioid antagonist, naltrexone to directly decrease marijuana self-administration by decreasing its acute effects. Hypotheses: naltrexone will 1) decrease the subjective and behavioral effects of smoked marijuana, 2) decrease marijuana self- administration, and 3) decrease the development of marijuana dependence, evidenced by fewer symptoms of abstinence. Thus, naltrexone may be a useful treatment medication in two ways: by decreasing both marijuana smoking and the development of marijuana dependence. Although smoked marijuana is one of the most widely abused drugs in the world, little is known about effective treatments for marijuana abuse and dependence. The strength of this protocol lies in the utilization of a controlled laboratory setting to examine the interactive effects of potential treatment medications with marijuana self-administration and a range of its behavioral effects. The data collected will suggest more efficacious approaches to treating marijuana abusers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
3P50DA009236-06S1
Application #
6366931
Study Section
Special Emphasis Panel (ZDA1)
Project Start
1999-09-30
Project End
2000-08-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$313,799
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications